研究発表 - 姉川　知史

Price Regulation and Competition in Japanese Pharmaceutical Market” July 1, 2004,

姉川 知史

2004 Far Eastern Meeting of the Econometric Society （Seoul, Korea, Yonsei University） , 

2004年07月

, 

口頭発表（一般）

　概要を見る

This paper studies Japanese pharmaceutical price control by using data on 39 cardiovascular pharmaceuticals in the period between 1985 and 1999. We estimate a relationship how demand is determined by official price, wholesale price, and other variables. This study finds that pharmaceuticals have fairly elastic coefficient with the wholesale price. This underscores importance of wholesale price reduction to gain demand. We find significant differences between new products and old products. For new products without generic entry, pharmaceutical firms tend to maintain official price as high as possible to achieve demand while they refrain from lowering wholesale price. For old products with generic competition, pharmaceutical firms resort to wholesale price competition. The government should distinguish old products from new products in its price control. This study also finds that product specific effects are more important than price related variables in determining pharmaceutical demand. Finally, this study finds that product specific effects have declined as products gets old up to 15 years after introduction. Then product specific effects start to increase after 15 years, which fact shows generic competition has not been fully realized in Japanese market.

Costs and Benefits of M&A-A Case for the Japanese Pharmaceutical Firms

姉川 知史

日本経済学会秋季大会 （岡山市，岡山大学） , 

2004年09月

, 

口頭発表（一般）, 日本経済学会

　概要を見る

This study investigates why Japanese pharmaceutical firms did not experience any large-scale M&A activities in the 1990s. By using the equation weighing the costs and effects of M&A, I analyze the possibilities of M&A of some twenty Japanese pharmaceutical firms and found that the large-scale firms in the mid-1990 could not enjoy higher efficiency in terms of “fundamental value.” Although the advantage of large-scale firms had become clear in the late 1990s, the possibility of M&A had become less due to higher stock prices of target firms. Possible combinations of the M&A are limited to several large-scale firms or efficient firms.
In sum, M&A of Japanese pharmaceutical firms have been “too few” in number and “too small” in scale in the past. Most of M&A are “too late” due to high stock price. “Only a few” combinations will be available in the early 2000s.

Geographical Variance and Convergence of Medical Cost in Japan

姉川 知史

International Health Economics Association, 5-th World Congress （Universitat Pompeu Fabra, Barcelona,Catalonia, Spain） , 

2005年07月

, 

口頭発表（一般）

Price Regulation and Competition in Japanese Pharmaceutical Market

姉川 知史

International Health Economics Association, 5-th World Congress （Universitat Pompeu Fabra, Barcelona,Catalonia, Spain） , 

2005年07月

, 

口頭発表（一般）

Price Regulation and Competition in Japanese Pharmaceutical Market-Anti-infective Case”

姉川 知史

2006 Far Eastern Meeting of the Econometric Society （Tsinghua University，Beijing, China） , 

2006年07月

, 

口頭発表（一般）

Geographical Variance and Convergence of Health, Medical Cost, Social Common Capital in Japan

姉川 知史

International Health Economics Association, 6-th World Congress （Copenhagen） , 

2007年07月

, 

口頭発表（一般）, international Health Economic Association

Price Regulation of Pharmaceutical Products- National Health Insurance and Efficiency of R&D

姉川 知史

American Society of Health Economists, 2nd biennial conference （Duke University, Durham, North Carolina） , 

2008年06月

, 

口頭発表（一般）, American Society of Health Economists

Geographical Variation and Convergence of Medical Services and Social Capital

姉川 知史

European Conference Health Economics （Helsinki, Finland） , 

2010年07月

, 

口頭発表（一般）, European Conference Health Economics

Pharmaceutical R&D division of labour in the past 30 years- patent analysis

姉川 知史

Patent Statistics for Decision Makers （Vienna, Austria） , 

2010年11月

, 

口頭発表（一般）, European Patent Office, OECD

世界の医薬品承認の長期動向分析1982－2005

姉川 知史

日本経済学会春季大会 （熊本学園大学，熊本市，熊本県） , 

2011年05月

, 

口頭発表（一般）, 日本経済学会

Analysis of Worldwide Drug Introduction: Why is Japan Behind the Rest of the World?

姉川 知史

9th EUROPEAN CONFERENCE ON HEALTH ECONOMICS （Dublin, Ireland） , 

2012年07月

, 

口頭発表（一般）, European Health Economics Association

Geographical Variation and Convergence of Medical Cost in Japan, Western Economic Association International

姉川 知史

10th Biennial Pacific Rim Conference Preliminary Program （Keio University, Tokyo, Japan） , 

2013年03月

, 

口頭発表（一般）, Western Economic Association International

Pharmaceutical Price and Demand in Japan

姉川 知史

10th World Congress in Health Economics, Health Economics in the Age of Longevity （Dublin, Ireland） , 

2014年07月

, 

口頭発表（一般）, International Health Economics Association and European Health Economics Association

Geographic variation and convergence of medical　cost-medical administrative area analysis of Japan

姉川 知史

Asian Meeting of Econometric Society （Dublin, Ireland） , 

2014年06月

, 

口頭発表（一般）, Econometric Society

Time Differences of the World Drug Introduction－Why was Japan behind the Worldwide Convergence?

姉川 知史

iHEA World Congress （Milan, Italy） , 

2015年07月

, 

口頭発表（一般）, International Health Economics Association,

Geographical Variation and Convergence of Health in Japan－Medical Resources, Services, and Outcome

姉川 知史

European Economic Association （Helsinki, Finland） , 

2015年08月

, 

口頭発表（一般）, European Conference Health Economics